Nama's AI scorecard currently rates Sotera Health Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is SHC's P/E ratio?

Sotera Health trades at a trailing price-to-earnings ratio of 16.2.

When does SHC report earnings?

Sotera Health's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.27.

What is the SHC price target?

The median analyst price target from 9 analysts is $22.00, with a range of $15.00 – $25.00.

Is SHC Shariah compliant?

Nama's AAOIFI-style screen reads Sotera Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Sotera Health (SHC)

Healthcare · Diagnostics Research · NASDAQ

Sotera Health (SHC) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $4.57B, a trailing price-to-earnings ratio of 16.2 and a free-cash-flow yield of 3.2%. Over the most recent reported fiscal year, revenue grew 5.7% and free cash flow per share grew 229.1%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +11.8% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-41.5%

How far the last close sits under the highest price of the past five years.

Market cap	$4.57B
Trailing P/E	16.2
Price / book	6.9
Price / sales	3.8
FCF yield	3.2%
Dividend yield	—
Gross margin	55.0%
Operating margin	32.8%
Net margin	13.4%
Revenue growth (YoY)	+5.7%
Revenue growth (3-yr annual)	+5.0%
EPS growth (YoY)	+22.9%
FCF/share growth (YoY)	+229.1%
Beta	1.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

SHC earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $0.27). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.29	$0.27	+7.4%	$324.89M
Q2 2026	Aug 6, 2026	$0.26	$0.24	+8.3%	$321.38M
Q1 2026	May 5, 2026	$0.18	$0.17	+5.9%	$280.05M
Q4 2025	Feb 24, 2026	$0.26	$0.24	+8.3%	$303.44M

SHC analyst price target

Median target $22.00 from 9 analysts, ranging $15.00 – $25.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live SHC data on Nama Insights →

SHC FAQ

Is SHC a buy?: Nama's AI scorecard currently rates Sotera Health Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is SHC's P/E ratio?: Sotera Health trades at a trailing price-to-earnings ratio of 16.2.
When does SHC report earnings?: Sotera Health's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.27.
What is the SHC price target?: The median analyst price target from 9 analysts is $22.00, with a range of $15.00 – $25.00.
Is SHC Shariah compliant?: Nama's AAOIFI-style screen reads Sotera Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.